Skip to content

ORBI-PHARMA INTERNATIONAL

Active
Private limited companyfounded 2008active for 18 yearsDorpsstraat 17, 3360 Bierbeek, BelgiumKBO/BCE: BE 0899.434.280
Summary

ORBI-PHARMA INTERNATIONAL has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€247,268) and a net result of -€42,359. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 5% of 10,753 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is 0.8% (low).

Risk analysisFollow ReportCompare
ORBI-PHARMA INTERNATIONALActiveChecked score 53/100
Risk analysis ReportCompare

Overview

Activity
Business and other management consultancy
NACE 70200Wholesale of pharmaceutical and medical goods NACE 46460
1 site
Size
€161,674total assets 2025
Staff
2.2 FTE
Equity
-€247,268
Loss
-€42,359
Turnover not published (abbreviated format)
Financial health
53 Fair Checked score 2025
Bankruptcy probabilitywithin 12 months
0.8%
Structure
2025 accounts filed 27 days late1 of 6 deeds summarised
Why 53raises riskCapped at 59: negative equityLoss of €42,359, the second in a row (financial year 2025)Negative equity -€247,268lowers riskSize: total assets €161,674Sector: Activities of head offices; management consultancy activities (NACE 70)Show the evidence

Checked score

Score 2025
53 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 8% of its sector peers (NACE 70, micro)
Negative equity caps the score at 59. Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Weak
Solvency 0=
equity -152.9% of total assets
Liquidity 1-1
short-term debt 252.9% · cash 0.6%
Profitability 0=
return on assets -26.2%
Bankruptcy probability, 12 months
0.8% Low
0%0.5%1.5%4%10%≥ 25%

About 8 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (48,438 companies, NACE 70, micro)
Last 24 months 11-2024: 3.4% 12-2024: 3.2%▼ -0.2 percentage points vs 11-2024 01-2025: 3.6%▲ +0.4 percentage points vs 12-2024 02-2025: 3.5%▼ -0.1 percentage points vs 01-2025 03-2025: 3.7%▲ +0.2 percentage points vs 02-2025highest value 04-2025: 3.1%▼ -0.6 percentage points vs 03-2025 05-2025: 3.1%● unchanged vs 04-2025 06-2025: 3.1%● unchanged vs 05-2025 07-2025: 3.1%● unchanged vs 06-2025 08-2025: 3.1%● unchanged vs 07-2025 09-2025: 3.0%▼ -0.1 percentage points vs 08-2025 10-2025: 3.0%● unchanged vs 09-2025 11-2025: 2.9%▼ -0.1 percentage points vs 10-2025 12-2025: 2.8%▼ -0.1 percentage points vs 11-2025 01-2026: 3.0%▲ +0.2 percentage points vs 12-2025 02-2026: 2.8%▼ -0.2 percentage points vs 01-2026 03-2026: 0.9%▼ -1.9 percentage points vs 02-2026 04-2026: 0.9%● unchanged vs 03-2026 05-2026: 0.9%● unchanged vs 04-2026 06-2026: 0.9%● unchanged vs 05-2026 07-2026: 0.9%● unchanged vs 06-2026 08-2026: 0.9%● unchanged vs 07-2026 09-2026: 0.9%● unchanged vs 08-2026 10-2026: 0.8%▼ -0.1 percentage points vs 09-2026lowest value
No credit on open account
Liquidity insufficient (current ratio 0.36, compared with 0.4 in 2024, below 1; short-term debt: 252.9% and cash: 0.6% of total assets), and equity is negative.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 70, micro): better than 3% on solvency, 2% on liquidity, 4% on profitability and 22% on growth.

The bankruptcy probability was computed on 25-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises risk
lowers risk · Size: total assets €161,674
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
raises risk · Loss of €42,359, the second in a row (financial year 2025)
NBB · annual accounts
raises risk · Negative equity -€247,268
NBB · annual accounts
lowers risk · Sector: Activities of head offices; management consultancy activities (NACE 70)
KBO
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025
Equity per financial year
19202122232425
2019 to 2025 · latest year -€247,268
raises risk · 2025 accounts filed 27 days late
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 27-02-2026, 27 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filings
Deviation from the deadline
2025
27 days late
2024
27 days late
2023
16 days late
2022
4 days early
2021
4 days early
2020
3 days early
2019
7 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 7 days after the deadline; the sector median (NACE 70) for financial year 2024 is 9 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-06-2026 is due by 31-01-2027. Nothing is late today. The company usually files around 16 February (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
30-06-2026 year end26-10-2026 today31-01-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Resignations: Buelens Jo (zaakvoerder,thans bestuurder) and…Appointments: Buelens Jo (director) and…
  2. Annual accounts filedfinancial year 2025 · abbreviated…
  3. Annual accounts filedfinancial year 2024 · abbreviated…

Key points

  • Risk: Negative equityfinancial year 2025: debts exceed assets -€247,268 View
  • Risk: 3 loss-making years in a rowloss financial year 2025 -€42,359 View
  • Caution: Among the weakest 5% on solvencysector median 52.4% · 10,753 companies -152.9% View
  • New directorslatest change 07-05-2026 · 2 in office 2 joined View

By topic

Financials

Financial year
2025
Total assets
€161,674
Loss
-€42,359
Solvency
-152.9%
Total assets▼ 8.8%
Net result
20192025
Go to Financials

Timeline

Events
19
Since
2011
Next accounts
by 31-01-2027
  1. 16-02-2024Annual accounts filed
  2. 30-06-2023Weakest financial year
  3. 27-01-2023Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Business and other management consultancyNACE 70200
Founded
23-07-2008
Year ends
30-06
Peppol
Reachable for e-invoices
Go to Company details

Articles of association

Provisions read
14
Purpose
“Het verstrekken van advies,management,raadgeving en expertises aan natuurlijke en…” (deed in Dutch)
Go to Articles of association

Key facts about ORBI-PHARMA INTERNATIONAL

What is the company number of ORBI-PHARMA INTERNATIONAL?
0899.434.280. In Belgium the VAT number is the company number with BE in front: BE 0899.434.280.
Where is ORBI-PHARMA INTERNATIONAL based?
The registered office is at Dorpsstraat 17, 3360 Bierbeek.Company details
What does ORBI-PHARMA INTERNATIONAL do?
According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
What is the legal form of ORBI-PHARMA INTERNATIONAL?
Private limited company (BV).
When was ORBI-PHARMA INTERNATIONAL founded?
On 23-07-2008.
Is ORBI-PHARMA INTERNATIONAL still active?
Yes, ORBI-PHARMA INTERNATIONAL is an active enterprise in the KBO register.
How many employees does ORBI-PHARMA INTERNATIONAL have?
On average 2.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of ORBI-PHARMA INTERNATIONAL?
Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is ORBI-PHARMA INTERNATIONAL profitable?
In financial year 2025, ORBI-PHARMA INTERNATIONAL made a loss of €42,359.
Where can I find the annual accounts of ORBI-PHARMA INTERNATIONAL?
ORBI-PHARMA INTERNATIONAL filed 16 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of ORBI-PHARMA INTERNATIONAL due?
By 31-01-2027, for financial year 2026.Timeline

Companies related to ORBI-PHARMA INTERNATIONAL

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What support did similar companies receive that this one did not?Subsidies How does this company compare with its sector?Sector benchmark

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure